
Oncology
Ivonescimab Extends Survival in EGFR-Variant NSCLC
Ivonescimab plus chemotherapy prolonged median overall survival after EGFR-TKI therapy, but toxicity, generalizability and US regulatory status shape its relevance.
Rayan Salih · September 14, 2026 · 7 min
